Skip to main content
ECI Knowledge Centre

The primary knowledge resource for cannabis practitioners

Articles, regulatory intelligence and research from the European Cannabis Institute. Evidence-based, practitioner-authored, updated as the industry evolves.

Articles Regulatory Updates Research Intelligence Reports
ECI Articles

Cannabis GMP and regulatory articles for practitioners

Evidence-based analysis of GMP, validation, regulatory science and quality management — written for professionals working in the European cannabis sector.

Regulation
What EU GMP Annex 1 (2022) means for cannabis manufacturers
Clause 4.4 mandates a Contamination Control Strategy for all medicinal product manufacturers — including non-sterile cannabis facilities. Here is what that means in practice.
Read article →
Cultivation
The GACP to GMP handover — where most facilities get it wrong
The transition from agricultural to pharmaceutical standards is the most critical and most frequently mismanaged boundary in the cannabis supply chain.
Read article →
Quality Science
CBN as a stability marker — what your CoA is telling you
Cannabinol is formed when THC degrades. A rising CBN content signals product age, storage failure or manufacturing quality issues.
Read article →
Validation
Five cleaning validation failures inspectors find every time
PDE-based limits, swab recovery correction, worst-case sampling — five systematic gaps that appear in cannabis facilities repeatedly.
Read article →
Markets
How Germany's compliance expectations are reshaping Europe
What BfArM requires today is a reliable indicator of what the broader European regulatory environment will require within two to three years.
Read article →
GMP Practice
What a Qualified Person needs from a cannabis batch record
Every batch record, analytical result and deviation report exists to support one decision: the QP certification. Here is what that evidence must include.
Read article →
Quality Science
The THC-to-CBD cross-contamination risk nobody talks about
Cannabis facilities processing multiple product types on shared equipment face a cross-contamination scenario with direct patient safety implications.
Read article →
Process Validation
Decarboxylation as a validated process step
A temperature setting and a timer is not process validation. Here is what demonstrating control of the most potency-critical step in cannabis manufacturing actually requires.
Read article →
CSV
Why your LIMS needs to be validated before your process is
Process validation data is only as trustworthy as the system recording it. An unvalidated LIMS is an unvalidated data foundation.
Read article →
Strategy
SOMF — measuring where your facility sits on the pharmaceuticalisation journey
The Strategic Operational Maturity Framework gives cannabis operators a structured method for understanding GMP readiness and prioritising what to fix first.
Read article →
Regulatory Intelligence

European cannabis regulatory updates by market

Key regulatory developments across European cannabis markets, monitored and summarised by the ECI team.

EU June 2026

EMA Annex 1 (2022) — CCS guidance clarified for non-sterile manufacturers

The EMA has confirmed that the Contamination Control Strategy requirement under Annex 1 Clause 4.4 applies to all medicinal product manufacturers, not only sterile facilities. Non-sterile cannabis manufacturers are required to maintain a documented CCS.
Germany May 2026

BfArM updates import authorisation assessment criteria

The Federal Institute for Drugs and Medical Devices has updated its assessment framework for cannabis import authorisations to include explicit requirements for computer system validation documentation and cleaning validation with PDE-based limits.
Portugal April 2026

Infarmed publishes updated cannabis manufacturing guidance

Infarmed has published updated guidance on cannabis manufacturing licence requirements, including clarification on the GACP-to-GMP transition point and documentation requirements for the material transfer interface.
Spain March 2026

AEMPS consults on medical cannabis regulatory framework

The Spanish Agency for Medicines and Medical Devices has opened a consultation on the proposed medical cannabis regulatory framework, including GMP certification requirements for licensed manufacturers and importers.
Netherlands February 2026

Bureau Medicinale Cannabis updates quality specifications

The BMC has updated the quality specifications for medicinal cannabis products, including revised cannabinoid profile requirements and new stability testing guidance for registered cannabis medicines.
EU January 2026

ICH Q9 (R1) formally adopted into EU GMP framework

The revised ICH Q9 Quality Risk Management guideline has been formally adopted into the EU GMP framework, with updated guidance on risk-based approaches to quality decision-making including contamination control and cleaning validation.
Regulatory information is provided for general guidance only and may not reflect the most current position of the relevant authority. Always verify directly with the national competent authority before making regulatory or compliance decisions. ECI accepts no liability for decisions made on the basis of this summary information.
ECI Research

Research informing the ECI cannabis curriculum

ECI course content is grounded in academic research and peer-reviewed science. The following works directly inform the ECI curriculum.

Phytomedicine

Cannabinoid complexation with hydroxypropyl-β-cyclodextrin: stability and dissolution enhancement

Dr. A. Ribeiro et al. · iMed.ULisboa, Universidade de Lisboa
Research into cyclodextrin complexation as a pharmaceutical strategy for improving cannabinoid bioavailability and formulation stability. Direct relevance to pharmaceutical cannabis drug delivery system development.
Regulatory Science

Strategic Operational Maturity Framework for pharmaceutical cannabis manufacturing

G. McPolin · University of Salford / GMP Life Sciences Consulting
Development and validation of a seven-dimension maturity assessment framework for evaluating pharmaceutical readiness across licensed cannabis manufacturing facilities. Basis of the ECI Pharmaceuticalisation Index™.
Quality Systems
GMP inspection readiness in European cannabis facilities: a gap analysis
ECI Research · European Cannabis Institute
Forthcoming. A systematic analysis of GMP compliance gaps identified across European licensed cannabis facilities, drawing on facility assessment data and regulatory inspection findings. Q4 2026.
Clinical Science
Endocannabinoid modulation and therapeutic applications: a pharmaceutical review
Dr. A. Ribeiro · iMed.ULisboa
Forthcoming. A pharmaceutical science review of the endocannabinoid system and evidence base for cannabinoid therapeutics, developed as foundational curriculum content for the CCPS pathway. Q3 2026.
Research collaboration ECI is actively developing research partnerships with European universities and research institutions. If you are a researcher working in pharmaceutical cannabis science, regulatory affairs, or GMP compliance and are interested in collaboration, contact us at info@ec-institute.eu.
Intelligence Reports

Inaugural Report · Q4 2026

State of European Cannabis Compliance

The inaugural ECI Intelligence Report publishes Q4 2026. Drawing on the industry survey, regulatory map data and facility benchmarking, it will be the most comprehensive assessment of GMP compliance maturity across the European cannabis sector ever published.

Register for early access
Primary survey data from 100+ European cannabis operators
Regulatory maturity benchmarking across 11+ markets
GMP readiness gap analysis by facility type and market
Pharmaceuticalisation Index™ aggregate scoring
Compliance investment trends and priorities
Regulatory outlook for 2027 and beyond
Authoritative regulatory sources

Key regulatory references

ECI content is grounded in the primary regulatory documents that govern pharmaceutical cannabis manufacturing across Europe. The following sources are the authoritative references for the requirements discussed in ECI courses and articles.

European Commission
EU GMP Guidelines — EudraLex Volume 4 ↗

The primary EU GMP regulatory framework including Annex 1, Annex 11, Annex 15 and all Part I and Part II requirements.

European Medicines Agency
EMA Quality Guidelines — ICH Q Series ↗

ICH Q8, Q9, Q10 and Q11 quality guidelines formally adopted into the EU GMP framework, covering pharmaceutical development, risk management and quality systems.

EMCDDA / EUDA
European Drug Agency — Cannabis Overview ↗

European Union Drugs Agency (formerly EMCDDA) monitoring and analysis of cannabis policy, market trends and regulatory developments across member states.

External links open in a new tab. ECI is not affiliated with and does not represent any of the above regulatory bodies. Links are provided for reference only.